# A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma

> **NCT00507130** · PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 36 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** MEDI528 0.3 mg/kg
- **BIOLOGICAL:** MEDI528 1 mg/kg
- **BIOLOGICAL:** MEDI528 3 mg/kg
- **OTHER:** PLACEBO

## Key facts

- **NCT ID:** NCT00507130
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-07
- **Final completion:** 2008-09
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2013-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00507130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00507130, "A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00507130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*